People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies find

Injected medications used to treat diabetes and obesity have been found to increase the risk of a rare side effect known as stomach paralysis, according to recent data. Several studies using large patient record databases show that the risk of developing gastroparesis is higher for individuals taking GLP-1 agonist medications compared to those who do not. Although the studies have not been reviewed by external experts or published in medical journals, the preliminary data suggests a consistent and rare risk of gastroparesis associated with GLP-1 medications. These medications, such as Wegovy and Zepbound, are in high demand due to their effectiveness in weight loss. However, they can also cause vomiting and slow down the stomach, potentially leading to the development of gastroparesis. While gastroparesis usually improves after stopping the medication, some individuals report that their condition does not improve even months later. The risk of gastroparesis appears to be approximately 50% higher in individuals taking GLP-1 medications compared to those who do not. Studies highlight that the incidence of gastroparesis is rare but consistent among patients taking GLP-1 medications. The risk is statistically significant and independent of diabetes. It is recommended that individuals considering GLP-1 medications be aware of the potential gastrointestinal side effects and the possibility of drug discontinuation.